Trials / Completed
CompletedNCT03778047
A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch
A Clinical Study for Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Hinova Pharmaceuticals Inc. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study for evaluating enzalutamide pharmacokinetics and pharmacodynamics, and related changes after drug switch in Chinese patients with metastatic castration-resistant prostate cancer. The study primary objective is to evaluate the pharmacokinetic characteristics of enzalutamide in Chinese patients with mCRPC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enzalutamide | oral |
| DRUG | HC1119 | oral |
Timeline
- Start date
- 2018-02-07
- Primary completion
- 2018-10-24
- Completion
- 2019-08-28
- First posted
- 2018-12-19
- Last updated
- 2020-11-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03778047. Inclusion in this directory is not an endorsement.